Taken together, these results demonstrate that in EV resistant cell line models and a subset of patients who acquire EV resistance but retain tumor NECTIN4 expression, that alternative NECTIN4-targeting strategies such as CAR T cell therapy remain effective, informing future sequencing strategies of these therapies. Here, NECTIN4 is linked to neoplasm.